Mineralys Therapeutics (MLYS) Profit After Tax (2022 - 2026)

Mineralys Therapeutics has disclosed Profit After Tax across 5 years of filings, most recently posting -$39.3 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$39.3 million, up 6.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$151.8 million (up 19.48% YoY), and the FY2025 annual result was -$154.7 million, up 13.02% from the prior year.
• Profit After Tax came in at -$39.3 million for Q1 2026 at Mineralys Therapeutics, down from -$32.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$6.5 million in Q2 2022 to a low of -$56.3 million in Q3 2024.
• The 5-year median for Profit After Tax is -$31.5 million (2024), against an average of -$27.9 million.
• Across the five-year window, Profit After Tax plunged 240.82% in 2023 and jumped 34.45% in 2025, its largest moves.
• Mineralys Therapeutics' Profit After Tax stood at -$9.1 million in 2022, then sank by 168.81% to -$24.4 million in 2023, then tumbled by 100.69% to -$48.9 million in 2024, then jumped by 34.11% to -$32.3 million in 2025, then dropped by 21.98% to -$39.3 million in 2026.
• The last three Profit After Tax figures came in at -$39.3 million (Q1 2026), -$32.3 million (Q4 2025), and -$36.9 million (Q3 2025), per Business Quant data.